Interphase microtubules: Chief casualties in the war on cancer?

Drug Discovery Today

Volumn 19, Issue 7, 2014, Pages 824-829

  Ogden, Angela ^a   Rida, Padmashree C G ^a   Reid, Michelle D ^b   Aneja, Ritu ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MICROTUBULE TARGETING AGENT; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CELL DEATH; CELL FUNCTION; CELL MIGRATION; CELL ORGANELLE; CENTROSOME; DRUG EFFICACY; DRUG TARGETING; HUMAN; IMMUNOCOMPETENT CELL; INTERPHASE; MICROTUBULE; MITOCHONDRIAL PERMEABILITY; MITOSIS; NERVE FIBER TRANSPORT; REVIEW; TUMOR GROWTH; WHOLE CELL; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; NEOPLASMS; PHYSIOLOGY; PROCEDURES; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; INTERPHASE; MICROTUBULES; NEOPLASMS;

EID: 84903773181     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.10.022     Document Type: Short Survey

References (62)

1. E. Komlodi-Pasztor et al. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale Clin. Cancer Res. 18 2012 51 63
2. T.J. Mitchison The proliferation rate paradox in antimitotic chemotherapy Mol. Biol. Cell 23 2012 1 6
3. E. Komlodi-Pasztor et al. Mitosis is not a key target of microtubule agents in patient tumors Nat. Rev. Clin. Oncol. 8 2011 244 250
4. P.P. Goodell et al. Comparison of methods for proliferative index analysis for grading pancreatic well-differentiated neuroendocrine tumors Am. J. Clin. Pathol. 137 2012 576 582
5. M. Andereef Cell proliferation and differentiation W.K. Hong, Holland Frei Cancer Medicine 2009 People's Medical Publishing House 26 39
6. S. Yachida et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer Nature 467 2010 1114 1117
7. J. Sjostrom et al. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer Clin. Cancer Res. 6 2000 3103 3110 (Pubitemid 30637734)
8. H.C. Kolberg et al. Relationship between chemotherapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and expression of proliferation markers and tumour suppressor gene p53 in human ovarian cancer xenografts in nude mice Eur. J. Gynaecol. Oncol. 26 2005 398 402
9. R. Perez-Soler et al. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice Clin. Cancer Res. 6 2000 4932 4938 (Pubitemid 32110439)
10. C. Oehler et al. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial Oncology 83 2012 1 9
11. J.R. Daniels et al. Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs J. Clin. Oncol. 2 1984 1192 1199 (Pubitemid 15202691)
12. A. Chakravarty et al. Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase Cancer Res. 71 2011 675 685
13. A. Cervantes et al. Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors Clin. Cancer Res. 18 2012 4764 4774
14. T. Macarulla et al. Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics Mol. Cancer Ther. 9 2010 2844 2852
15. P. Schoffski et al. A Phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours Eur. J. Cancer 48 2012 179 186
16. D. Olmos et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies Clin. Cancer Res. 17 2011 3420 3430
17. H.J. Khoury et al. A Phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias Cancer 118 2012 3556 3564
18. J.R. Infante et al. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors Cancer Chemother. Pharmacol. 69 2012 165 172
19. K. Holen et al. A Phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors Invest. New Drugs 30 2012 1088 1095
20. J.J. Lee, and S.M. Swain Peripheral neuropathy induced by microtubule-stabilizing agents J. Clin. Oncol. 24 2006 1633 1642 (Pubitemid 46638788)
21. E.B. Masurovsky et al. Taxol effects on glia in organotypic mouse spinal cord-DRG cultures Cell Biol. Int. Rep. 9 1985 539 546 (Pubitemid 15052222)
22. R. Djaldetti et al. Vincristine-induced alterations in Schwann cells of mouse peripheral nerve Am. J. Hematol. 52 1996 254 257 (Pubitemid 26288736)
23. F. Hellal et al. Microtubule stabilization reduces scarring and causes axon regeneration after spinal cord injury Science 331 2011 928 931
24. G. Gallo, and P.C. Letourneau Different contributions of microtubule dynamics and transport to the growth of axons and collateral sprouts J. Neurosci. 19 1999 3860 3873 (Pubitemid 29222262)
25. S. Binet et al. Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules Int. J. Cancer 46 1990 262 266 (Pubitemid 20252087)
26. D.M. Suter et al. Microtubule dynamics are necessary for SRC family kinase-dependent growth cone steering Curr. Biol. 14 2004 1194 1199 (Pubitemid 38893983)
27. A. Chiorazzi et al. Experimental epothilone B neurotoxicity: results of in vitro and in vivo studies Neurobiol. Dis. 35 2009 270 277
28. N.E. Lapointe et al. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy Neurotoxicology 37 2013 231 239
29. A.A. Argyriou et al. Peripheral nerve damage associated with administration of taxanes in patients with cancer Crit. Rev. Oncol. Hematol. 66 2008 218 228
30. B. Zhang et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice J. Neurosci. 32 2012 3601 3611
31. V. Sengottuvel et al. Taxol facilitates axon regeneration in the mature CNS J. Neurosci. 31 2011 2688 2699
32. C. Dumontet, and M.A. Jordan Microtubule-binding agents: a dynamic field of cancer therapeutics Nat. Rev. Drug Discov. 9 2010 790 803
33. M. Thadani-Mulero et al. Androgen receptor on the move: boarding the microtubule expressway to the nucleus Cancer Res. 72 2012 4611 4615
34. M.L. Zhu et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer Cancer Res. 70 2010 7992 8002
35. H. Li et al. Effects of paclitaxel on EGFR endocytic trafficking revealed using quantum dot tracking in single cells PLoS One 7 2012 e45465
36. N.J. Mabjeesh et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF Cancer Cell 3 2003 363 375 (Pubitemid 38340305)
37. P. Giannakakou et al. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics Proc. Natl. Acad. Sci. U. S. A. 99 2002 10855 10860
38. K. Rathinasamy, and D. Panda Kinetic stabilization of microtubule dynamic instability by benomyl increases the nuclear transport of p53 Biochem. Pharmacol. 76 2008 1669 1680
39. M. Carbonaro et al. Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repression J. Cell Biol. 192 2011 83 99
40. M. Carbonaro et al. Microtubules regulate hypoxia-inducible factor-1alpha protein trafficking and activity: implications for taxane therapy J. Biol. Chem. 287 2012 11859 11869
41. I. Kaverina, and A. Straube Regulation of cell migration by dynamic microtubules Semin. Cell Dev. Biol. 22 2011 968 974
42. J. Magdalena et al. Microtubule involvement in NIH 3T3 Golgi and MTOC polarity establishment J. Cell Sci. 116 2003 743 756 (Pubitemid 36231312)
43. J. Wehland et al. Role of microtubules in the distribution of the Golgi apparatus: effect of taxol and microinjected anti-alpha-tubulin antibodies Proc. Natl. Acad. Sci. U. S. A. 80 1983 4286 4290 (Pubitemid 13077822)
44. C. Hayot et al. In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton Int. J. Oncol. 21 2002 417 425
45. J.F. Kidd et al. Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore J. Biol. Chem. 277 2002 6504 6510 (Pubitemid 34968448)
46. C. Tari et al. Action of vinca alkaloides on calcium movements through mitochondrial membrane Pharmacol. Res. Commun. 18 1986 519 528 (Pubitemid 16073693)
47. H. Zheng et al. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy Exp. Neurol. 232 2011 154 161
48. S. Shimizu et al. Essential role of voltage-dependent anion channel in various forms of apoptosis in mammalian cells J. Cell Biol. 152 2001 237 250 (Pubitemid 34285595)
49. J.Y. Chan A clinical overview of centrosome amplification in human cancers Int. J. Biol. Sci. 7 2011 1122 1144
50. W.L. Lingle, and J.L. Salisbury Altered centrosome structure is associated with abnormal mitoses in human breast tumors Am. J. Pathol. 155 1999 1941 1951
51. W.L. Lingle et al. Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity Proc. Natl. Acad. Sci. U. S. A. 95 1998 2950 2955 (Pubitemid 28135835)
52. A. Ogden et al. Heading off with the herd: how cancer cells might maneuver supernumerary centrosomes for directional migration Cancer Metastasis Rev. 32 2013 269 287
53. A. Ogden et al. Let's huddle to prevent a muddle: centrosome declustering as an attractive anticancer strategy Cell Death Differ. 19 2012 1255 1267
54. A. Sevko et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model J. Immunol. 190 2013 2464 2471
55. A. Javeed et al. Paclitaxel and immune system Eur. J. Pharm. Sci. 38 2009 283 290
56. I. Pellicciotta et al. Epothilone B enhances Class I HLA and HLA-A2 surface molecule expression in ovarian cancer cells Gynecol. Oncol. 122 2011 625 631
57. N. Liu et al. Selective impairment of CD4+ CD25+ Foxp3+ regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis Int. Immunopharmacol. 11 2011 212 219
58. G.V. Shurin et al. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism J. Immunol. 183 2009 137 144
59. R. Wehner et al. Impact of chemotherapeutic agents on the immunostimulatory properties of human 6-sulfo LacNAc+ (slan) dendritic cells Int. J. Cancer 132 2013 1351 1359
60. S.W. Lowe et al. Intrinsic tumour suppression Nature 432 2004 307 315 (Pubitemid 39551658)
61. D.R. Green, and G.I. Evan A matter of life and death Cancer Cell 1 2002 19 30 (Pubitemid 41039172)
62. P. Karna et al. A novel microtubule-modulating agent EM011 inhibits angiogenesis by repressing the HIF-1alpha axis and disrupting cell polarity and migration Carcinogenesis 33 2012 1769 1781